AdaptHealth Corp. (NASDAQ:AHCO) Receives $11.67 Average Target Price from Brokerages

Shares of AdaptHealth Corp. (NASDAQ:AHCO) have received an average rating of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $11.67.

Several analysts have issued reports on AHCO shares. UBS Group lowered their target price on AdaptHealth from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Truist Financial decreased their price objective on AdaptHealth from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Royal Bank of Canada cut their target price on AdaptHealth from $13.00 to $11.00 and set an “outperform” rating for the company in a research note on Tuesday, November 19th. Robert W. Baird reduced their target price on AdaptHealth from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Finally, Canaccord Genuity Group lowered their price target on shares of AdaptHealth from $14.00 to $13.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th.

Institutional Investors Weigh In On AdaptHealth

Several hedge funds have recently bought and sold shares of AHCO. FMR LLC raised its position in shares of AdaptHealth by 9.3% during the 3rd quarter. FMR LLC now owns 7,350,549 shares of the company’s stock valued at $82,547,000 after buying an additional 624,645 shares in the last quarter. Reinhart Partners LLC. increased its stake in AdaptHealth by 45.2% in the third quarter. Reinhart Partners LLC. now owns 6,198,642 shares of the company’s stock valued at $69,611,000 after acquiring an additional 1,929,339 shares during the last quarter. State Street Corp raised its position in AdaptHealth by 19.8% during the third quarter. State Street Corp now owns 4,124,284 shares of the company’s stock valued at $46,316,000 after purchasing an additional 681,816 shares in the last quarter. Segall Bryant & Hamill LLC lifted its stake in AdaptHealth by 15.5% during the third quarter. Segall Bryant & Hamill LLC now owns 3,701,808 shares of the company’s stock worth $41,571,000 after purchasing an additional 496,453 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of AdaptHealth by 12.2% in the 3rd quarter. Geode Capital Management LLC now owns 2,451,173 shares of the company’s stock worth $27,532,000 after purchasing an additional 265,712 shares in the last quarter. 82.67% of the stock is currently owned by institutional investors.

AdaptHealth Price Performance

AHCO opened at $9.53 on Thursday. AdaptHealth has a 1 year low of $6.46 and a 1 year high of $11.90. The company has a debt-to-equity ratio of 1.34, a current ratio of 1.24 and a quick ratio of 1.00. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -5.78, a P/E/G ratio of 1.36 and a beta of 1.10. The firm’s fifty day moving average price is $10.04 and its two-hundred day moving average price is $10.42.

AdaptHealth (NASDAQ:AHCO) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.02). The firm had revenue of $805.90 million during the quarter, compared to the consensus estimate of $809.32 million. AdaptHealth had a positive return on equity of 9.62% and a negative net margin of 6.57%. The company’s revenue for the quarter was up .2% on a year-over-year basis. During the same period in the previous year, the company posted $0.19 earnings per share. As a group, analysts anticipate that AdaptHealth will post 0.88 earnings per share for the current fiscal year.

AdaptHealth Company Profile

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.